Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print May 27, 2004, 10.1148/radiol.2321030876
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2321030876v1
232/1/160    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zuo, C. S.
Right arrow Articles by Rofsky, N. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zuo, C. S.
Right arrow Articles by Rofsky, N. M.
(Radiology 2004;232:160-163.)
© RSNA, 2004

Experimental Studies

MR Imaging of the Stomach: Potential Use for Mangafodipir Trisodium— A Study in Swine1

Chun S. Zuo, PhD, Peter R. Seoane, PhD, Jiani Hu, PhD, Philip P. Harnish, PhD and Neil M. Rofsky, MD

1 From the Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass (C.S.Z., N.M.R.); Eagle Vision Pharmaceutical, Exton, Pa (P.R.S., P.P.H.); and Department of Radiology, Wayne State University, Detroit, Mich (J.H.). Received May 29, 2003; revision requested August 12; final revision received November 12; accepted November 24. Supported in part by grant DK 58420–1 from the NIH to Eagle Vision Pharmaceutical. Address correspondence to C.S.Z., Brain Imaging Center, McLean Hospital, 115 Mill St, Belmont, MA 02215 (e-mail: czuo@mclean.harvard.edu).

PURPOSE: To evaluate mangafodipir trisodium as a potential contrast agent at magnetic resonance (MR) imaging of the stomach.

MATERIALS AND METHODS: Mangafodipir trisodium was injected intravenously into three swine at a dose of 5 µmol per kilogram of body weight. For comparison, gadopentetate dimeglumine was injected into three other swine at a dose of 0.1 mmol per kilogram of body weight. T1-weighted three-dimensional MR images were acquired in all six swine at 1.5 T before and approximately 10, 15, 20, 25, 30, and 40 minutes after contrast material administration. Extracted stomach specimens were imaged at 3.0 T. In vivo and ex vivo images were evaluated visually and quantitatively for contrast enhancement of the stomach, and in vivo images were evaluated for the presence of reflux from the duodenum.

RESULTS: Mangafodipir trisodium produced prolonged and selective enhancement of the inner surface of the stomach, in contrast to the more general enhancement seen with gadopentetate dimeglumine, and reflux from the duodenum could not account for this selective enhancement. Ex vivo images confirmed that T1 enhancement in the stomach wall with mangafodipir trisodium was limited to the inner surface. Gadopentetate dimeglumine did not produce selective enhancement of the inner surface of the stomach.

CONCLUSION: Mangafodipir trisodium preferentially enhances the inner surface of the stomach on MR images acquired in swine and, therefore, may have potential for use as a contrast agent at MR imaging of the human stomach.

© RSNA, 2004

Index terms: Animals • Experimental study • Magnetic resonance (MR), contrast media • Stomach, MR, 72.12143, 72.121412, 72.121415 • Stomach, mucosa